<DOC>
	<DOCNO>NCT00650767</DOCNO>
	<brief_summary>This Phase 2 study , involve 12-week treatment period , design evaluate effectiveness investigational study drug ARRY-438162 treating rheumatoid arthritis patient stable dos methotrexate , evaluate safety study drug . Approximately 200 patient US , Argentina , Brazil , Hungary , Peru , Poland Romania enrol study .</brief_summary>
	<brief_title>A Study ARRY-438162 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key Diagnosis rheumatoid arthritis , base American College Rheumatology ( ACR ) 1987 Revised Criteria , prior first dose study drug . Patient receive stable dose methotrexate ≥ 6 week prior first dose study drug willing continue regimen duration study . Patient receive stable dose folate ≥ 6 week willing continue regimen duration study . No prior use biological agent treatment rheumatoid arthritis . Additional criterion exist . Key Diagnosis inflammatory noninflammatory arthritis may interfere disease activity assessments clinically apparent osteoarthritis would affect subsequent efficacy measure . A history severe , progressive , and/or uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological disease severe systemic involvement rheumatoid arthritis . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>